Free tool
Heavily traded stocks
We cover 83 companies whose typical session turns over more than $10.00M. The median market value in the group is $2.99B. Across the group, the median move over the past trading day is +0.79%. 70% of the 83 with a 200-day average trade above it. Price change over the past year runs from −27.8% to +47.8% across the middle 80 percent of the group, with a median of +4.3%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
Table
83 of 7,336 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| AZN.L | AstraZeneca PLC | $264.05B | Mega cap | +5.65% |
| AZN.ST | AstraZeneca PLC | $258.56B | Mega cap | +6.22% |
| NOVO-B.CO | Novo Nordisk A/S | $210.20B | Mega cap | −11.26% |
| NOV.DE | Novo Nordisk A/S | $209.27B | Mega cap | +15.22% |
| SAN.PA | Sanofi | $109.36B | Large cap | −2.60% |
| GSK.L | GSK plc | $104.16B | Large cap | +30.59% |
| EL.PA | EssilorLuxottica Société anonyme | $85.31B | Large cap | −38.15% |
| MRK.DE | Merck KGaA | $70.28B | Large cap | +32.17% |
| BAYN.DE | Bayer Aktiengesellschaft | $56.25B | Large cap | +76.91% |
| SHL.DE | Siemens Healthineers AG | $51.23B | Large cap | −14.18% |
| HLN.L | Haleon plc | $44.62B | Large cap | +2.68% |
| FRE.DE | Fresenius SE & Co. KGaA | $30.43B | Large cap | +1.64% |
| DIM.PA | Sartorius Stedim Biotech S.A. | $21.78B | Large cap | +11.64% |
| GMAB.CO | Genmab A/S | $20.69B | Large cap | +36.19% |
| SRT3.DE | Sartorius Aktiengesellschaft | $19.68B | Large cap | +25.88% |
| SOBI.ST | Swedish Orphan Biovitrum AB (publ) | $16.99B | Large cap | +61.26% |
| IPN.PA | Ipsen S.A. | $15.97B | Large cap | +40.80% |
| COLO-B.CO | Coloplast A/S | $15.96B | Large cap | −20.60% |
| ERF.PA | Eurofins Scientific SE | $14.64B | Large cap | +15.60% |
| ORNBV.HE | Orion Oyj | $13.16B | Large cap | +21.01% |
| FME.DE | Fresenius Medical Care AG | $12.64B | Large cap | −2.61% |
| REC.MI | Recordati Industria Chimica e Farmaceutica S.p.A. | $12.57B | Large cap | +1.80% |
| SN.L | Smith & Nephew plc | $12.18B | Large cap | −22.42% |
| BIM.PA | bioMérieux S.A. | $10.22B | Large cap | −35.91% |
| ABVX.PA | ABIVAX Société Anonyme | $10.21B | Large cap | +48.91% |
| DEMANT.CO | Demant A/S | $9.36B | Mid cap | +17.12% |
| QIA.DE | Qiagen N.V. | $8.99B | Mid cap | −6.73% |
| ALK-B.CO | ALK-Abelló A/S | $7.26B | Mid cap | +5.09% |
| GETI-B.ST | Getinge AB (publ) | $7.01B | Mid cap | +20.89% |
| HLUN-B.CO | H. Lundbeck A/S | $6.47B | Mid cap | +8.99% |
| CTEC.L | Convatec Group PLC | $6.01B | Mid cap | −1.95% |
| SECT-B.ST | Sectra AB (publ) | $5.63B | Mid cap | −17.02% |
| HIK.L | Hikma Pharmaceuticals PLC | $4.61B | Mid cap | −9.62% |
| MCOV-B.ST | Medicover AB (publ) | $3.85B | Mid cap | −8.20% |
| CAMX.ST | Camurus AB (publ) | $3.79B | Mid cap | −15.35% |
| ZEAL.CO | Zealand Pharma A/S | $3.34B | Mid cap | −25.94% |
| BIOA-B.ST | BioArctic AB (publ) | $3.00B | Mid cap | +12.31% |
| ASKER.ST | Asker Healthcare Group AB (publ) | $2.99B | Mid cap | −24.65% |
| AMBU-B.CO | Ambu A/S | $2.69B | Mid cap | −19.13% |
| BAVA.CO | Bavarian Nordic A/S | $2.51B | Mid cap | −7.97% |
| ONT.L | Oxford Nanopore Technologies plc | $2.41B | Mid cap | −2.24% |
| EKTA-B.ST | Elekta AB (publ) | $2.20B | Mid cap | +26.10% |
| GN.CO | GN Store Nord A/S | $2.13B | Mid cap | −18.50% |
| ALIF-B.ST | AddLife AB (publ) | $2.08B | Mid cap | −7.20% |
| GNS.L | Genus plc | $2.08B | Mid cap | −12.94% |
| ATT.ST | Attendo AB (publ) | $1.77B | Small cap | +80.74% |
| BONEX.ST | Bonesupport Holding AB (publ) | $1.57B | Small cap | −28.26% |
| AMBEA.ST | Ambea AB (publ) | $1.45B | Small cap | +38.66% |
| VITR.ST | Vitrolife AB (publ) | $1.35B | Small cap | −30.23% |
| CHEMM.CO | ChemoMetec A/S | $1.33B | Small cap | −3.94% |
| UPR.L | Uniphar plc | $1.33B | Small cap | +6.94% |
| SPI.L | Spire Healthcare Group plc | $1.28B | Small cap | +7.25% |
| BIOG-B.ST | BioGaia AB (publ) | $1.23B | Small cap | +13.96% |
| CVSG.L | CVS Group plc | $1.20B | Small cap | +2.05% |
| XVIVO.ST | Xvivo Perfusion AB (publ) | $929.27M | Small cap | +59.31% |
| DYVOX.ST | Dynavox Group AB (publ) | $850.75M | Small cap | −39.29% |
| OXB.L | Oxford Biomedica plc | $847.14M | Small cap | −9.81% |
| AMS.L | Advanced Medical Solutions Group plc | $830.96M | Small cap | +38.01% |
| SNT.WA | Synektik Spólka Akcyjna | $774.15M | Small cap | +53.07% |
| CRW.L | Craneware plc | $588.10M | Small cap | −40.83% |
| RAY-B.ST | RaySearch Laboratories AB (publ) | $564.79M | Small cap | −29.98% |
| HNSA.ST | Hansa Biopharma AB (publ) | $450.66M | Small cap | +35.65% |
| AVCT.L | Avacta Group Plc | $440.62M | Small cap | +26.36% |
| PRTC.L | PureTech Health plc | $398.28M | Small cap | −4.27% |
| NIOX.L | NIOX Group Plc | $392.35M | Small cap | −9.49% |
| CRNA.OL | Circio Holding ASA | $384.19M | Small cap | +1733.85% |
| OPT.L | Optima Health plc | $355.51M | Small cap | +9.32% |
| ANCR.L | Animalcare Group PLC | $314.33M | Small cap | +28.86% |
| TSTL.L | Tristel plc | $276.02M | Small cap | +19.76% |
| SCLP.L | Scancell Holdings plc | $136.80M | Small cap | −7.62% |
| BVXP.L | Bioventix PLC | $124.26M | Small cap | −30.64% |
| EAH.L | ECO Animal Health Group plc | $89.77M | Micro cap | +34.69% |
| POLB.L | Poolbeg Pharma PLC | $82.41M | Micro cap | +164.62% |
| MPAL.L | MedPal AI PLC | $44.20M | Micro cap | −40.00% |
| ALNEV.PA | Neovacs S.A. | $22.00 | Micro cap | −11.29% |
| ALC.SW | Alcon Inc. | — | — | −7.46% |
| GALD.SW | Galderma Group AG | — | — | +22.58% |
| LONN.SW | Lonza Group AG | — | — | +4.28% |
| NOVN.SW | Novartis AG | — | — | +30.24% |
| ROP.SW | Roche Holding AG | — | — | +47.60% |
| SDZ.SW | Sandoz Group AG | — | — | +47.80% |
| SOON.SW | Sonova Holding AG | — | — | +6.01% |
| STMN.SW | Straumann Holding AG | — | — | −2.20% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.